ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NERV Minerva Neurosciences Inc

2.49
0.15 (6.41%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Minerva Neurosciences Inc NASDAQ:NERV NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.15 6.41% 2.49 2.49 2.52 2.59 2.334 2.34 31,299 21:30:00

Current Report Filing (8-k)

21/03/2017 10:32am

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2017

 

 

Minerva Neurosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36517   26-0784194

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

1601 Trapelo Road

Suite 284

Waltham, MA

  02451
(Address of principal executive offices)   (Zip Code)

(Registrant’s telephone number, including area code): (617) 600-7373

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On March 16, 2017 and March 17, 2017, certain investors in Minerva Neurosciences, Inc.’s (the “Company”) previously announced March 2015 private placement exercised their warrants. Upon exercise, the Company issued the investors an aggregate of 1,418,439 shares of the Company’s common stock. The Company received gross proceeds of $8,187,229.91 from the exercise prices of the exercised warrants.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

MINERVA NEUROSCIENCES, INC.
By:   /s/ Mark S. Levine
Name:   Mark S. Levine
Title:   Senior Vice President, General Counsel and Secretary

Date: March 21, 2017

1 Year Minerva Neurosciences Chart

1 Year Minerva Neurosciences Chart

1 Month Minerva Neurosciences Chart

1 Month Minerva Neurosciences Chart

Your Recent History

Delayed Upgrade Clock